New Betulinic Acid Derivatives for Bevirimat-Resistant Human Immunodeficiency Virus Type-1

Citations Over TimeTop 10% of 2013 papers

Abstract

Bevirimat (1, BVM) is an anti-HIV agent that blocks HIV-1 replication by interfering with HIV-1 Gag-SP1 processing at a late stage of viral maturation. However, clinical trials of 1 have revealed a high baseline drug resistance that is attributed to naturally occurring polymorphisms in HIV-1 Gag. To overcome the drug resistance, 28 new derivatives of 1 were synthesized and tested against compound 1-resistant (BVM-R) HIV-1 variants. Among them, compound 6 exhibited much improved activity against several HIV-1 strains carrying BVM-R polymorphisms. Compound 6 was at least 20-fold more potent than 1 against the replication of NL4-3/V370A, which carries the most prevalent clinical BVM-R polymorphism in HIV-1 Gag-SP1. Thus, compound 6 merits further development as a potential anti-AIDS clinical trial candidate.

Related Papers

• → Isolation of a cytopathogenic virus from a case of porcine reproductive and respiratory syndrome (PRRS) and its characterization as parainfluenza virus type 2(1998)30 cited
• → Characterization of an H3N2 triple reassortant influenza virus with a mutation at the receptor binding domain (D190A) that occurred upon virus transmission from turkeys to pigs(2010)9 cited
• → Orf virus and vaccinia virus do not cross-protect sheep(1988)17 cited
• → The Virulence of West Nile Virus and TP 21 Virus and Their Application to a Group B Arbor Virus Vaccine(1961)15 cited
• → Characterization of cytopathogenicity of classical swine fever virus isolate induced by Newcastle disease virus(2015)